Home › Quarterly results › Hospitals & Healthcare Services
Hospitals & Healthcare Services: Q1 FY27 results (April-June 2026)
31 companies have declared Hospitals & Healthcare Services Q1 FY27 results so far, the latest on 28 Sep 2026.
Across the 24 non-financial companies with a year-ago quarter to compare, sales grew +28.2% and net profit +4.9% year on year, and the combined operating margin narrowed 94 bps to 22.6%.
75% of companies grew net profit; 1 turned a loss into a profit; 29% beat their own profit trend and 38% fell short of it.
Latest results
Results calendar
Q2 FY27 Q1 FY27 Q4 FY26 Q3 FY26 Q2 FY26
Hospitals & Healthcare Services Q1 FY27 scoreboard
Sales growth
+28.2%
YoY, 24 companies combined; median +20.0%
Net profit growth
+4.9%
YoY combined; median +25.7%
Operating margin
22.6%
-94 bps YoY
Grew profit
75%
1 turnaround, 0 into loss
Vs own profit trend
29% / 38%
above / below, 33% in line
Price since results
-8.1%
median; 12% of 25 stocks up
Other-income heavy
7
25%+ of pre-tax profit from other income & one-offs
Latest Hospitals & Healthcare Services Q1 FY27 results 31
Page 1 of 2
Tap ☆ on any company to add it to My companies. Your list stays in this browser.
M Cap ₹451 Cr
P/E —
PEG —
Since results -6.0%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
— —
25.3 — — Operating profit
— —
5.0 — — OPM %
— —
19.9% — — Other income
— —
0.1 — — Net profit
— —
2.8 — — PAT margin %
— —
11.0% — — EPS (₹)
— —
1.78 — —
Quality of profit
Pre-tax profit ₹3.8 Cr: core business ₹3.7 Cr, other income ₹0.1 Cr.
Core profit YoY: —
AI read of the filing MOMSBELIEF Q1 FY27 Cons PAT at Rs 27.87 Mn vs Loss YoY; Acquires City Pro Group Positive Consolidated revenue from operations surged 136.4% YoY to INR 253.14 million from INR 107.06 million Consolidated PAT turned around to INR 27.87 million versus a loss of INR 5.37 million in Q1 FY26 USA segment generated INR 128.23 million (50.66% of total revenue) compared to INR 8.96 million in Q1 FY26 Full analysis →
M Cap ₹92,247 Cr
P/E —
PEG —
Since results -6.1%
Exceptional items of ₹-13.4 Cr in the quarter
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
— —
1,048 — — Operating profit
— —
250 — — OPM %
— —
23.9% — — Other income
— —
40.9 — — Net profit
— —
116 — — PAT margin %
— —
11.0% — — EPS (₹)
— —
0.98 — —
Quality of profit
Pre-tax profit ₹152 Cr: core business ₹124 Cr, other income ₹40.9 Cr, exceptional & other items −₹13.4 Cr.
Core profit YoY: —
AI read of the filing Manipal Health Approves Q1 Results, Appoints PW as Auditor & Proposes Governance Changes Neutral Approved standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. Appointed M/s Price Waterhouse Chartered Accountants LLP for a 5-year term from the 16th AGM (2026) to the 21st AGM (2031). Proposed AoA amendment granting Temasek Group up to 3 board seats and MGHS Group up to 2 seats, subject to maintaining a minimum 6% equity stake. Full analysis →
M Cap ₹1,451 Cr
P/E —
PEG —
Since results +35.3%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
— —
34.3 — — Operating profit
— —
8.4 — — OPM %
— —
24.4% — — Other income
— —
0.7 — — Net profit
— —
5.3 — — PAT margin %
— —
15.5% — — EPS (₹)
— —
0.66 — —
Quality of profit
Pre-tax profit ₹7.0 Cr: core business ₹6.3 Cr, other income ₹0.7 Cr.
Core profit YoY: —
AI read of the filing Gujarat Kidney Submits Unaudited Standalone & Consolidated Q1 Results Ended June 30, 2026 Neutral Board approved unaudited standalone and consolidated financial results for Q1 ended June 30, 2026. Statutory auditor Y. M. Shah & Co. issued a clean limited review report with no qualifications on August 14, 2026. Compliance fulfilled under Regulation 33 of SEBI Listing Obligations and Disclosure Requirements. Full analysis →
M Cap ₹1,737 Cr
P/E 17.8
PEG 0.99
Since results -3.5%
Profit -32% below its own trend Operating margin contracted 202 bps YoY 32% of pre-tax profit came from other income and one-off items
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+22.1% +22.0%
236 193 193 Operating profit
+12.8% +5.4%
58.0 55.0 51.4 OPM %
-202 bps -388 bps
24.6% 28.5% 26.6% Other income
+83.3% -77.4%
7.2 32.0 4.0 Net profit
-19.3% -60.6%
16.6 42.0 20.5 PAT margin %
-361 bps -1473 bps
7.0% 21.8% 10.6% EPS (₹)
-19.7% -60.3%
5.10 12.86 6.35
Quality of profit
Pre-tax profit ₹22.4 Cr: core business ₹15.2 Cr, other income ₹7.2 Cr.
Core profit YoY: -35.3%
· reported profit -19.3%
Cash & debt
FY26 cash from operations ₹143 Cr:
141% of FY26 net profit of ₹102 Cr.
Borrowings ₹534 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹207 ₹236
+13.9% above Net profit ₹24.3 ₹16.6
-31.8% below
AI read of the filing KRSNAA Q1 Revenue Up 22% to ₹235.5 Cr; Promoters to Infuse Capital via 16.21 Lakh Warrants Watch Revenue from operations grew 22.1% YoY to ₹235.53 Cr from ₹192.98 Cr in the previous year's quarter. Net profit for the quarter fell to ₹16.55 Cr vs ₹20.52 Cr YoY, impacted by finance costs rising to ₹14.83 Cr. Preferential issue of 16.21 lakh warrants to promoters approved at a floor price of ₹565 per warrant. Full analysis →
M Cap ₹770 Cr
P/E —
PEG —
Since results -16.7%
46% of pre-tax profit came from other income and one-off items
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
— —
19.4 — — Operating profit
— —
2.4 — — OPM %
— —
12.5% — — Other income
— —
1.1 — — Net profit
— —
1.8 — — PAT margin %
— —
9.2% — — EPS (₹)
— —
0.25 — —
Quality of profit
Pre-tax profit ₹2.4 Cr: core business ₹1.3 Cr, other income ₹1.1 Cr.
Core profit YoY: —
AI read of the filing Gaudium IVF Q1 PAT at ₹1.66 Cr; IPO Debt Repayment of ₹18.07 Cr Completed Neutral Revenue from operations stood at ₹13.67 cr for the quarter ended June 30, 2026. Net profit decreased to ₹1.66 cr from ₹7.73 cr in the preceding quarter (March 2026). Completed repayment of ₹18.07 cr in borrowings using IPO proceeds, achieving zero-debt status. Full analysis →
M Cap ₹86,021 Cr
P/E 59.0
PEG 5.90
Since results -12.2%
Profit -18% below its own trend
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+16.7% +10.4%
2,366 2,143 2,028 Operating profit
+14.4% -1.2%
598 606 523 OPM %
-50 bps -299 bps
25.3% 28.3% 25.8% Other income
+11.0% -15.6%
40.5 48.0 36.5 Net profit
+4.9% -5.6%
323 342 308 PAT margin %
-154 bps -231 bps
13.6% 16.0% 15.2% EPS (₹)
+4.7% -5.7%
3.32 3.52 3.17
Quality of profit
Pre-tax profit ₹436 Cr: core business ₹396 Cr, other income ₹40.5 Cr.
Core profit YoY: +8.8%
· reported profit +4.9%
Cash & debt
FY26 cash from operations ₹1,633 Cr:
113% of FY26 net profit of ₹1,442 Cr.
Borrowings ₹3,478 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹2,406 ₹2,366
-1.6% in line Net profit ₹395 ₹323
-18.2% below
AI read of the filing ₹425 Cr Capex for Vaishali Expansion and Entry into Medical Education Positive ₹425 Crore approved for 'Tower 3' construction at Max Super Speciality Hospital, Vaishali. Addition of ~250 beds (202 census, 48 non-census) to the existing 387-bed Vaishali facility. Network-wide capacity utilization reported at >75% for the quarter ended June 30, 2026. Full analysis →
M Cap ₹1,418 Cr
P/E 38.3
PEG —
Since results -16.1%
Profit -24% below its own trend Operating margin contracted 146 bps YoY 38% of pre-tax profit came from other income and one-off items Profit grew faster than the core business (core profit -22%) FY26 operating cash flow was only 0% of profit
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+11.7% +15.4%
331 287 296 Operating profit
+0.1% +43.4%
41.6 29.0 41.5 OPM %
-146 bps +245 bps
12.6% 10.1% 14.0% Other income
+5.8% -7.3%
7.4 8.0 7.0 Net profit
+36.7% -41.7%
10.5 18.0 7.7 PAT margin %
+58 bps -310 bps
3.2% 6.3% 2.6% EPS (₹)
+38.0% -42.4%
0.98 1.70 0.71
Quality of profit
Pre-tax profit ₹19.7 Cr: core business ₹12.3 Cr, other income ₹7.4 Cr.
Core profit YoY: -21.5%
· reported profit +36.7%
Cash & debt
FY26 cash from operations ₹0.0 Cr:
0% of FY26 net profit of ₹34.2 Cr.
Borrowings ₹595 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹316 ₹331
+4.9% in line Net profit ₹13.8 ₹10.5
-24.2% below
AI read of the filing Shalby Q1 Revenue Grows 11.7% YoY to ₹331 Cr; Appoints Shanay Shah as Whole-Time Director Neutral Consolidated revenue for Q1 FY27 reached ₹331.22 Cr, up 11.7% YoY from ₹296.43 Cr. Healthcare Services segment revenue grew to ₹288.81 Cr, contributing 87% of total revenue. Manufacturing & Trading of Implants segment reported a loss of ₹11.48 Cr, widening from a ₹9.91 Cr loss in Q1 FY26. Full analysis →
M Cap ₹1,647 Cr
P/E 47.0
PEG 0.77
Since results +15.3%
Profit +36% above its own trend Operating margin expanded 201 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+20.7% +7.7%
87.6 81.4 72.6 Operating profit
+28.2% +24.9%
30.4 24.4 23.8 OPM %
+201 bps +480 bps
34.7% 29.9% 32.7% Other income
+20.1% +37.7%
1.1 0.8 0.9 Net profit
+40.0% +108.5%
12.8 6.2 9.2 PAT margin %
+202 bps +709 bps
14.7% 7.6% 12.6% EPS (₹)
+38.9% +106.6%
2.50 1.21 1.80
Quality of profit
Pre-tax profit ₹16.5 Cr: core business ₹15.4 Cr, other income ₹1.1 Cr.
Core profit YoY: +33.5%
· reported profit +40.0%
Cash & debt
FY26 cash from operations ₹82.0 Cr:
261% of FY26 net profit of ₹31.4 Cr.
Borrowings ₹130 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹88.8 ₹87.6
-1.3% in line Net profit ₹9.5 ₹12.8
+35.5% above
AI read of the filing Suraksha Diagnostic Q1 PAT Rises 37% YoY to ₹12.58 Cr; Appoints New Group CFO Positive Standalone Revenue from operations increased 15.8% YoY to ₹84.09 cr in Q1 FY27. Standalone Net Profit grew 37% YoY to ₹12.58 cr, up from ₹9.18 cr in Q1 FY26. Earnings Per Share (EPS) improved to ₹2.42 from ₹1.80 in the corresponding quarter last year. Full analysis →
M Cap ₹1,078 Cr
P/E 34.4
PEG 0.28
Since results -7.4%
Profit +31% above its own trend Operating margin expanded 105 bps YoY Operating cash flow was negative in FY26 despite a profit
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+13.2% +0.9%
74.7 74.0 66.0 Operating profit
+19.7% +2.6%
14.4 14.0 12.0 OPM %
+105 bps +31 bps
19.2% 18.9% 18.2% Other income
+14.9% +14.9%
2.3 2.0 2.0 Net profit
+28.9% +3.1%
10.3 10.0 8.0 PAT margin %
+169 bps +30 bps
13.8% 13.5% 12.1% EPS (₹)
+22.2% +2.2%
1.87 1.83 1.53
Quality of profit
Pre-tax profit ₹12.0 Cr: core business ₹9.7 Cr, other income ₹2.3 Cr.
Core profit YoY: +21.8%
· reported profit +28.9%
Cash & debt
FY26 cash from operations −₹5.0 Cr:
-17% of FY26 net profit of ₹29.0 Cr.
Borrowings ₹13.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹76.6 ₹74.7
-2.4% in line Net profit ₹7.9 ₹10.3
+30.9% above
AI read of the filing Laxmi Dental to acquire Palghar land for Rs 6.21 Cr; approves Q1 FY27 results Neutral Acquisition of land in Palghar for a total consideration of Rs 6.21 Cr for factory construction Advance payment of Rs 51 Lakhs already executed as part of the Letter of Intent Allotment of 59,360 equity shares at an exercise price of Rs 2 per share under ESOP 2024 Full analysis →
M Cap ₹6,198 Cr
P/E 72.9
PEG —
Since results -13.0%
Operating margin expanded 162 bps YoY Core business grew faster than reported profit (core profit +69%)
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+23.6% +5.9%
282 266 228 Operating profit
+33.1% +25.3%
63.9 51.0 48.0 OPM %
+162 bps +350 bps
22.7% 19.2% 21.1% Other income
+6.6% -37.8%
7.5 12.0 7.0 Net profit
+33.2% +6.6%
32.0 30.0 24.0 PAT margin %
+82 bps +7 bps
11.3% 11.3% 10.5% EPS (₹)
-75.6% +5.3%
3.19 3.03 13.10
Quality of profit
Pre-tax profit ₹41.0 Cr: core business ₹37.1 Cr, other income ₹7.5 Cr, exceptional & other items −₹3.6 Cr.
Core profit YoY: +68.8%
· reported profit +33.2%
AI read of the filing Nephroplus Approves Rs 709 Cr Asset Transfers and Expands into Kazakhstan Positive Entered into seven asset transfer arrangements for an aggregate consideration of Rs 709.30 crore during Q1 FY27. Utilized Rs 2,074.83 crore of IPO proceeds out of a total Rs 3,251.53 crore as of June 30, 2026. Internal restructuring of Saudi Arabian operations involving a 51% stake transfer for SAR 2.24 million. Full analysis →
M Cap ₹242 Cr
P/E 3054.1
PEG —
Since results -2.7%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
— —
17.1 — — Operating profit
— —
2.9 — — OPM %
— —
17.3% — — Other income
— —
0.2 — — Net profit
— —
0.6 — — PAT margin %
— —
3.6% — — EPS (₹)
— —
0.30 — —
Quality of profit
Pre-tax profit ₹1.0 Cr: core business ₹0.8 Cr, other income ₹0.2 Cr.
Core profit YoY: —
AI read of the filing LOTUSEYE Q1 Results: Net Profit up 12.6% YoY to Rs 0.61 Cr; Revenue grows 26% to Rs 17.06 Cr Positive Revenue from operations increased 26.2% YoY to Rs 17.06 Cr from Rs 13.52 Cr. Net profit for the quarter stood at Rs 0.61 Cr, up from Rs 0.54 Cr in the same quarter last year. Finance costs surged to Rs 50.65 lakhs from Rs 11.76 lakhs YoY, a 330.7% increase. Full analysis →
M Cap ₹926 Cr
P/E —
PEG —
Since results -5.5%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
— —
0.1 — — Operating profit
— —
-0.5 — — OPM %
— —
-632.0% — — Other income
— —
0.0 — — Net profit
— —
-0.5 — — PAT margin %
— —
-642.9% — — EPS (₹)
— —
-0.16 — —
Quality of profit
Pre-tax profit −₹0.5 Cr: core business −₹0.5 Cr, other income ₹0.0 Cr.
Core profit YoY: —
AI read of the filing Health X Platform Reports Q1 Net Loss of ₹51.43 Lakhs; Revenue Declines 17% YoY Negative Standalone net loss widened significantly to ₹51.43 lakhs in Q1 FY27 from ₹10.95 lakhs in Q1 FY26. Revenue from operations decreased by 17.3% YoY to ₹8.00 lakhs. Total expenses increased to ₹60.72 lakhs, primarily driven by 'Other Expenses' amounting to ₹50.30 lakhs. Full analysis →
M Cap ₹16,087 Cr
P/E 51.4
PEG 2.14
Since results -5.7%
Operating margin contracted 251 bps YoY 30% of pre-tax profit came from other income and one-off items
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+30.3% -1.8%
525 535 403 Operating profit
+17.9% +13.7%
125 110 106 OPM %
-251 bps +325 bps
23.8% 20.6% 26.3% Other income
-19.9% +75.8%
33.4 19.0 41.7 Net profit
-8.4% +31.2%
85.3 65.0 93.1 PAT margin %
-685 bps +408 bps
16.2% 12.1% 23.1% EPS (₹)
-7.6% +29.8%
8.49 6.54 9.19
Quality of profit
Pre-tax profit ₹117 Cr: core business ₹82.3 Cr, other income ₹33.4 Cr, exceptional & other items ₹1.6 Cr.
Core profit YoY: +3.0%
· reported profit -8.4%
Cash & debt
FY26 cash from operations ₹246 Cr:
77% of FY26 net profit of ₹321 Cr.
Borrowings ₹354 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹458 ₹525
+14.8% above Net profit ₹87.9 ₹85.3
-3.0% in line
AI read of the filing Q1 FY27 Results: Revenue Grows 30% YoY to ₹525 Cr; PAT Declines 8% to ₹85 Cr Neutral Consolidated Revenue from operations increased 30.3% YoY to ₹525.38 Cr from ₹403.21 Cr. Consolidated Net Profit (PAT) decreased 8.4% YoY to ₹85.27 Cr compared to ₹93.08 Cr in the year-ago quarter. Employee benefit expenses surged 70.6% YoY to ₹126.90 Cr, impacting operating margins. Full analysis →
M Cap ₹8,797 Cr
P/E 264.5
PEG —
Since results -12.4%
Profit +361% above its own trend 59% of pre-tax profit came from other income and one-off items Profit grew faster than the core business (core profit +133%)
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+13.1% +6.3%
693 652 613 Operating profit
+11.8% -3.6%
121 125 108 OPM %
-19 bps -179 bps
17.4% 19.2% 17.6% Other income
+96.7% from loss 14.8 -18.3 7.5 Net profit
+175.3% +307.4%
16.5 4.0 6.0 PAT margin %
+140 bps +175 bps
2.4% 0.6% 1.0% EPS (₹)
+187.5% +513.3%
0.92 0.15 0.32
Quality of profit
Pre-tax profit ₹25.0 Cr: core business ₹10.3 Cr, other income ₹14.8 Cr.
Core profit YoY: +132.7%
· reported profit +175.3%
Cash & debt
FY26 cash from operations ₹347 Cr:
1523% of FY26 net profit of ₹22.8 Cr.
Borrowings ₹1,735 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹706 ₹693
-1.8% in line Net profit ₹3.6 ₹16.5
+361.2% above
AI read of the filing HCG Q1 FY27 Net Profit Surges 190% to ₹13.77 Cr; Completes ₹37.64 Cr Milann Divestment Positive Consolidated Total Income grew 14.1% YoY to ₹707.23 Cr from ₹619.99 Cr. Net Profit attributable to equity holders surged 190% YoY to ₹13.77 Cr. Completed divestment of BACC Healthcare (Milann) for ₹37.64 Cr on June 29, 2026. Full analysis →
M Cap ₹3,016 Cr
P/E 16.0
PEG 0.57
Since results -9.9%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+11.3% +11.3%
406 365 365 Operating profit
+9.3% +30.8%
79.8 61.0 73.0 OPM %
-35 bps +294 bps
19.7% 16.7% 20.0% Other income
+20.3% +20.3%
8.4 7.0 7.0 Net profit
+9.5% +33.0%
55.9 42.0 51.0 PAT margin %
-22 bps +224 bps
13.8% 11.5% 14.0% EPS (₹)
+8.6% +33.8%
6.09 4.55 5.61
Quality of profit
Pre-tax profit ₹74.8 Cr: core business ₹66.4 Cr, other income ₹8.4 Cr.
Core profit YoY: +8.9%
· reported profit +9.5%
Cash & debt
FY26 cash from operations ₹167 Cr:
91% of FY26 net profit of ₹183 Cr.
Borrowings ₹37.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹398 ₹406
+2.0% in line Net profit ₹58.6 ₹55.9
-4.8% in line
AI read of the filing INDRAMEDCO Q1 PAT Up 8.5% YoY to ₹55.85 Cr; Revenue Grows 11.2% Positive Revenue from operations increased to ₹406.15 cr in Q1 FY27 from ₹365.06 cr in Q1 FY26. Net Profit (PAT) for the quarter stood at ₹55.85 cr, up from ₹51.46 cr in the previous year's corresponding quarter. Professional charges to doctors, a key expense, rose by 13.6% YoY to ₹111.15 cr. Full analysis →
M Cap ₹61,004 Cr
P/E 167.9
PEG —
Since results -18.3%
Profit -73% below its own trend Operating margin expanded 143 bps YoY Exceptional items of ₹-114 Cr in the quarter Core business grew faster than reported profit (core profit +52%)
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+21.6% +10.9%
1,311 1,182 1,078 Operating profit
+30.9% +18.0%
264 224 202 OPM %
+143 bps +122 bps
20.2% 19.0% 18.7% Other income
+27.7% +0.1%
37.0 37.0 29.0 Net profit
-68.9% -81.0%
29.3 154 94.0 PAT margin %
-649 bps -1079 bps
2.2% 13.0% 8.7% EPS (₹)
-81.2% -88.6%
0.31 2.71 1.65
Quality of profit
Pre-tax profit ₹78.1 Cr: core business ₹164 Cr, other income ₹37.0 Cr, exceptional & other items −₹123 Cr.
Core profit YoY: +51.7%
· reported profit -68.9%
Cash & debt
FY26 cash from operations ₹656 Cr:
153% of FY26 net profit of ₹428 Cr.
Borrowings ₹2,220 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹1,246 ₹1,311
+5.2% above Net profit ₹108 ₹29.3
-72.8% below
AI read of the filing Aster DM Q1 Revenue Grows 18% to ₹726 Cr; Reports ₹14 Cr Loss on ₹110 Cr Merger Costs Neutral Standalone revenue from operations increased 18.4% YoY to ₹725.73 Cr. Exceptional items of ₹109.79 Cr incurred for merger-related professional fees led to a net loss of ₹14.30 Cr. Merger with Quality Care India Limited (QCIL) officially became effective on July 1, 2026. Full analysis →
M Cap ₹10,979 Cr
P/E 54.1
PEG 4.92
Since results -7.4%
Operating margin expanded 145 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+16.6% +6.0%
450 425 386 Operating profit
+23.9% +2.9%
111 108 89.8 OPM %
+145 bps -74 bps
24.7% 25.4% 23.2% Other income
-32.1% -37.5%
5.1 8.2 7.5 Net profit
+25.7% +11.6%
56.9 51.0 45.2 PAT margin %
+91 bps +64 bps
12.6% 12.0% 11.7% EPS (₹)
-68.6% +11.0%
2.73 2.46 8.70
Quality of profit
Pre-tax profit ₹77.7 Cr: core business ₹72.6 Cr, other income ₹5.1 Cr.
Core profit YoY: +35.2%
· reported profit +25.7%
Cash & debt
FY26 cash from operations ₹351 Cr:
184% of FY26 net profit of ₹191 Cr.
Borrowings ₹232 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹475 ₹450
-5.3% below Net profit ₹57.1 ₹56.9
-0.4% in line
AI read of the filing Metropolis Q1 FY27: Net Profit Rises 42% YoY to ₹50.6 Cr; Revenue Up 15% Positive Revenue from operations increased 15.2% YoY to ₹372.28 Cr from ₹323.27 Cr in the previous year. Net Profit after tax grew 42.2% YoY to ₹50.58 Cr, up from ₹35.58 Cr in Q1 FY26. Profit Before Tax (PBT) stood at ₹66.38 Cr, representing a 40% increase over the ₹47.38 Cr reported in the same quarter last year. Full analysis →
M Cap ₹15,144 Cr
P/E 81.8
PEG 6.30
Since results -1.6%
Profit -12% below its own trend Operating margin contracted 120 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+26.1% +8.9%
614 564 487 Operating profit
+20.9% +5.8%
170 161 141 OPM %
-120 bps -79 bps
27.8% 28.5% 29.0% Other income
-54.2% -54.2%
6.4 14.0 14.0 Net profit
+44.8% +10.0%
55.0 50.0 38.0 PAT margin %
+116 bps +10 bps
9.0% 8.9% 7.8% EPS (₹)
+50.5% +14.4%
1.43 1.25 0.95
Quality of profit
Pre-tax profit ₹75.1 Cr: core business ₹68.7 Cr, other income ₹6.4 Cr.
Core profit YoY: +29.7%
· reported profit +44.8%
Cash & debt
FY26 cash from operations ₹519 Cr:
309% of FY26 net profit of ₹168 Cr.
Borrowings ₹1,066 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹593 ₹614
+3.6% in line Net profit ₹62.2 ₹55.0
-11.5% below
AI read of the filing 44.6% PAT Growth in Q1 FY27; 18 New Facilities Added and Nigeria Expansion Announced Positive Revenue from operations grew 26.0% YoY to ₹614 Cr, driven by a 25.3% growth in the India business. Profit After Tax (PAT) surged 44.6% YoY to ₹55 Cr, with PAT margins improving to 8.9% from 7.6%. Added 18 new facilities in Q1 FY27, including a record 16 greenfield surgical facilities in a single quarter. Full analysis →
M Cap ₹28,230 Cr
P/E 145.2
PEG —
Since results -14.7%
Profit -24% below its own trend Operating margin contracted 319 bps YoY 31% of pre-tax profit came from other income and one-off items
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+35.3% +9.7%
1,180 1,075 872 Operating profit
+15.8% +8.4%
223 206 193 OPM %
-319 bps -22 bps
18.9% 19.2% 22.1% Other income
+148.6% —
17.4 1.0 7.0 Net profit
-56.0% +13.3%
37.4 33.0 85.0 PAT margin %
-658 bps +10 bps
3.2% 3.1% 9.7% EPS (₹)
-46.9% -1.9%
1.04 1.06 1.96
Quality of profit
Pre-tax profit ₹56.6 Cr: core business ₹39.2 Cr, other income ₹17.4 Cr.
Core profit YoY: -63.4%
· reported profit -56.0%
Cash & debt
FY26 cash from operations ₹511 Cr:
211% of FY26 net profit of ₹242 Cr.
Borrowings ₹4,253 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹1,116 ₹1,180
+5.7% above Net profit ₹49.4 ₹37.4
-24.3% below
AI read of the filing KIMS Q1 Results: Rs 1,500 Cr QIP Completed; Consolidated PAT Drops 47% YoY to Rs 41.5 Cr Watch Completed Rs 1,500 Cr QIP by issuing 1.98 Cr shares at Rs 755 each Consolidated PAT attributable to owners declined to Rs 41.5 Cr from Rs 78.6 Cr in the year-ago quarter Board approved a Rs 650 Cr limit for loans, guarantees, or securities to group entities Full analysis →
M Cap ₹34,923 Cr
P/E 42.8
PEG 3.56
Since results -16.0%
Operating margin contracted 485 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+78.0% +3.5%
2,684 2,594 1,507 Operating profit
+39.4% -7.5%
470 508 337 OPM %
-485 bps -208 bps
17.5% 19.6% 22.4% Other income
+49.1% +41.9%
35.5 25.0 23.8 Net profit
+5.4% -7.5%
207 224 197 PAT margin %
-533 bps -91 bps
7.7% 8.6% 13.1% EPS (₹)
+5.4% -6.9%
10.20 10.96 9.68
Quality of profit
Pre-tax profit ₹260 Cr: core business ₹227 Cr, other income ₹35.5 Cr, exceptional & other items −₹1.9 Cr.
Core profit YoY: +9.3%
· reported profit +5.4%
Cash & debt
FY26 cash from operations ₹1,621 Cr:
201% of FY26 net profit of ₹806 Cr.
Borrowings ₹5,857 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹2,071 ₹2,684
+29.6% above Net profit ₹208 ₹207
-0.2% in line
AI read of the filing NH Q1 FY27 Standalone Revenue up 16% YoY to ₹1,097 Cr; Operating Margins Contract to 17.5% Neutral Standalone Revenue from operations grew 16.3% YoY to ₹1,097.1 cr from ₹943.1 cr. Standalone Net Profit increased 57.8% YoY to ₹137.8 cr, though down 31.8% sequentially. Operating Margin (Standalone) contracted by 486 basis points YoY to 17.50%. Full analysis →
M Cap ₹8,383 Cr
P/E 44.8
PEG 1.15
Since results -22.0%
Operating margin contracted 319 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+18.2% +6.0%
411 388 348 Operating profit
+1.5% -11.1%
79.3 89.2 78.1 OPM %
-319 bps -370 bps
19.3% 23.0% 22.5% Other income
-17.7% +15.7%
10.6 9.1 12.9 Net profit
-14.5% -25.4%
37.5 50.3 43.9 PAT margin %
-349 bps -383 bps
9.1% 13.0% 12.6% EPS (₹)
-14.5% -25.3%
5.72 7.66 6.69
Quality of profit
Pre-tax profit ₹50.6 Cr: core business ₹40.0 Cr, other income ₹10.6 Cr.
Core profit YoY: -17.9%
· reported profit -14.5%
Cash & debt
FY26 cash from operations ₹268 Cr:
138% of FY26 net profit of ₹194 Cr.
Borrowings ₹584 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹417 ₹411
-1.4% in line Net profit ₹40.8 ₹37.5
-8.2% in line
AI read of the filing JLHL Q1 Net Profit Falls 14% YoY to ₹37.2 Cr; Acquires Pharma Unit for Backward Integration Neutral Revenue from operations grew 12.7% YoY to ₹328.49 cr in Q1 FY27. Net profit for the quarter stood at ₹37.19 cr, down from ₹43.29 cr in the same period last year. Acquired 100% of Sulcus Private Limited for ₹3.78 cr in a related-party transaction with promoters. Full analysis →
M Cap ₹12,683 Cr
P/E 43.7
PEG 4.37
Since results -19.3%
Core business grew faster than reported profit (core profit +39%)
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+33.2% +2.2%
470 460 353 Operating profit
+29.9% -7.1%
135 145 104 OPM %
-71 bps -287 bps
28.6% 31.5% 29.4% Other income
-36.5% +217.8%
12.7 4.0 20.0 Net profit
+16.2% -19.8%
62.5 78.0 53.8 PAT margin %
-194 bps -365 bps
13.3% 17.0% 15.2% EPS (₹)
+13.3% -21.3%
5.97 7.59 5.27
Quality of profit
Pre-tax profit ₹84.0 Cr: core business ₹71.2 Cr, other income ₹12.7 Cr.
Core profit YoY: +38.7%
· reported profit +16.2%
Cash & debt
FY26 cash from operations ₹420 Cr:
149% of FY26 net profit of ₹281 Cr.
Borrowings ₹891 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹386 ₹470
+21.7% above Net profit ₹65.3 ₹62.5
-4.2% in line
AI read of the filing ₹410.55 Cr Q1 Revenue; Rainbow Announces Mumbai Expansion & ₹19.8 Cr Nellore Acquisition Positive Standalone revenue rose 22.6% YoY to ₹410.55 cr in Q1 FY27 from ₹334.75 cr in Q1 FY26 Acquisition of 64% partnership interest in Super Prime Medical Care LLP (Nellore) for ₹19.8 cr Professional fees to doctors increased by 25.3% YoY to ₹108.73 cr, impacting bottom-line growth Full analysis →
M Cap ₹35,275 Cr
P/E 63.8
PEG 3.19
Since results -8.1%
Profit -24% below its own trend
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+26.5% +12.5%
1,304 1,159 1,031 Operating profit
+26.3% +17.5%
287 244 227 OPM %
-3 bps +94 bps
22.0% 21.1% 22.0% Other income
+8.3% -40.1%
22.2 37.0 20.5 Net profit
-1.1% +10.7%
157 142 159 PAT margin %
-336 bps -19 bps
12.1% 12.3% 15.4% EPS (₹)
-0.2% +10.3%
5.91 5.36 5.92
Quality of profit
Pre-tax profit ₹213 Cr: core business ₹191 Cr, other income ₹22.2 Cr.
Core profit YoY: +13.7%
· reported profit -1.1%
Cash & debt
FY26 cash from operations ₹714 Cr:
129% of FY26 net profit of ₹554 Cr.
Borrowings ₹1,190 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹1,229 ₹1,304
+6.1% above Net profit ₹207 ₹157
-24.2% below
AI read of the filing Medanta Q1 Revenue up 22% YoY; Guwahati Hospital Capacity Expanded to 650 Beds Positive Standalone revenue for Q1 FY27 reached ₹1,078.72 Cr, a 22.3% increase from ₹882.16 Cr in Q1 FY26. Guwahati hospital capacity revised upward by 250 beds to a total of 650 beds. Estimated investment for the Guwahati project is ₹970 Cr, representing approximately 24% of the company's current Net Worth. Full analysis →
M Cap ₹592 Cr
P/E 40.9
PEG —
Since results -12.4%
Turnaround: profit against a loss a year ago Operating margin expanded 1479 bps YoY 60% of pre-tax profit came from other income and one-off items
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+10.3% -52.7%
75.0 159 68.0 Operating profit
from loss -80.9%
4.2 22.2 -6.2 OPM %
+1479 bps -835 bps
5.7% 14.0% -9.1% Other income
+15.1% -67.9%
3.2 9.8 2.8 Net profit
from loss -80.9%
4.2 22.1 -6.1 PAT margin %
+1463 bps -830 bps
5.6% 13.9% -9.0% EPS (₹)
from loss -80.8%
0.95 4.96 -1.89
Quality of profit
Pre-tax profit ₹5.2 Cr: core business ₹2.1 Cr, other income ₹3.2 Cr.
Core profit YoY: from loss
AI read of the filing Fabtech Q1 Revenue Grows 10.2% to ₹74.98 Cr; Announces ₹0.60 Dividend Positive Consolidated revenue from operations increased to ₹74.98 crore in Q1 FY27 from ₹68.01 crore in Q1 FY26. Final dividend of ₹0.60 per equity share (face value ₹10) recommended for shareholder approval. UAE subsidiary (Fabtech Technologies LLC) reported standalone revenue of ₹28.51 crore and net profit of ₹3.81 crore. Full analysis →
M Cap ₹32,287 Cr
P/E 59.2
PEG 1.97
Since results +18.0%
Profit +22% above its own trend Operating margin expanded 237 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+19.1% +13.5%
798 703 670 Operating profit
+28.9% +32.4%
248 187 192 OPM %
+237 bps +443 bps
31.0% 26.6% 28.7% Other income
+13.9% +32.9%
31.9 24.0 28.0 Net profit
+27.2% +29.2%
170 132 134 PAT margin %
+137 bps +260 bps
21.4% 18.8% 20.0% EPS (₹)
-35.8% +29.5%
10.15 7.84 15.80
Quality of profit
Pre-tax profit ₹229 Cr: core business ₹197 Cr, other income ₹31.9 Cr.
Core profit YoY: +29.5%
· reported profit +27.2%
Cash & debt
FY26 cash from operations ₹636 Cr:
125% of FY26 net profit of ₹509 Cr.
Borrowings ₹199 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹744 ₹798
+7.2% above Net profit ₹140 ₹170
+21.7% above
AI read of the filing 27% PAT Growth in Q1; Rs 5 Dividend and New Acquisitions in Ghana & India Positive Revenue from operations increased 19.1% YoY to ₹797.7 Cr compared to ₹669.8 Cr in the previous year. Net Profit (PAT) rose 27.2% YoY to ₹170.5 Cr, with Basic EPS improving to ₹10.15 from ₹7.94. Declared an interim dividend of ₹5 per equity share, representing a 50% payout on face value. Full analysis →
M Cap ₹14,797 Cr
P/E 79.0
PEG 2.93
Profit +12% above its own trend Operating margin expanded 375 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+22.8% +5.3%
231 219 188 Operating profit
+34.6% +3.6%
99.0 95.5 73.5 OPM %
+375 bps -68 bps
42.9% 43.5% 39.1% Other income
+27.7% +275.0%
9.0 2.4 7.0 Net profit
+37.3% +10.6%
53.0 47.9 38.6 PAT margin %
+242 bps +110 bps
22.9% 21.8% 20.5% EPS (₹)
+37.2% +10.7%
5.16 4.66 3.76
Quality of profit
Pre-tax profit ₹71.0 Cr: core business ₹63.0 Cr, other income ₹9.0 Cr, exceptional & other items −₹1.0 Cr.
Core profit YoY: +39.5%
· reported profit +37.3%
Cash & debt
FY26 cash from operations ₹271 Cr:
157% of FY26 net profit of ₹173 Cr.
Borrowings ₹423 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹227 ₹231
+1.6% in line Net profit ₹47.1 ₹53.0
+12.4% above
M Cap ₹11,697 Cr
P/E 39.3
PEG —
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+19.3% +3.4%
476 460 399 Operating profit
+20.0% -1.1%
126 127 105 OPM %
+15 bps -119 bps
26.5% 27.7% 26.3% Other income
+14.3% +6.6%
8.0 7.5 7.0 Net profit
+34.8% +15.9%
89.0 76.8 66.0 PAT margin %
+216 bps +202 bps
18.7% 16.7% 16.5% EPS (₹)
+26.5% +7.3%
1.91 1.78 1.51
Quality of profit
Pre-tax profit ₹105 Cr: core business ₹97.0 Cr, other income ₹8.0 Cr.
Core profit YoY: +29.3%
· reported profit +34.8%
M Cap ₹7,953 Cr
P/E 45.3
PEG 1.26
Profit -23% below its own trend Operating margin expanded 216 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+24.3% +7.2%
240 224 193 Operating profit
+33.3% +2.5%
77.0 75.1 57.8 OPM %
+216 bps -145 bps
32.1% 33.5% 29.9% Other income
+7.5% +16.0%
5.0 4.3 4.7 Net profit
+33.2% +4.7%
51.0 48.7 38.3 PAT margin %
+141 bps -50 bps
21.2% 21.7% 19.8% EPS (₹)
-55.4% +9.7%
3.28 2.99 7.35
Quality of profit
Pre-tax profit ₹68.0 Cr: core business ₹64.0 Cr, other income ₹5.0 Cr, exceptional & other items −₹1.0 Cr.
Core profit YoY: +40.4%
· reported profit +33.2%
Cash & debt
FY26 cash from operations ₹213 Cr:
131% of FY26 net profit of ₹163 Cr.
Borrowings ₹51.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹234 ₹240
+2.6% in line Net profit ₹66.0 ₹51.0
-22.7% below
M Cap ₹6,430 Cr
P/E 25.1
PEG 0.90
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+15.3% +4.1%
431 414 374 Operating profit
+17.2% +11.7%
124 111 106 OPM %
+47 bps +196 bps
28.8% 26.8% 28.3% Other income
+23.3% -12.5%
7.0 8.0 5.7 Net profit
+20.6% +9.5%
69.0 63.0 57.2 PAT margin %
+71 bps +79 bps
16.0% 15.2% 15.3% EPS (₹)
+20.7% +9.1%
63.14 57.89 52.30
Quality of profit
Pre-tax profit ₹92.0 Cr: core business ₹84.0 Cr, other income ₹7.0 Cr, exceptional & other items ₹1.0 Cr.
Core profit YoY: +18.8%
· reported profit +20.6%
Cash & debt
FY26 cash from operations ₹362 Cr:
148% of FY26 net profit of ₹244 Cr.
Borrowings ₹403 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹431 ₹431
-0.0% in line Net profit ₹66.0 ₹69.0
+4.5% in line
M Cap ₹1,146 Cr
P/E 23.9
PEG 7.96
Profit +126% above its own trend Operating margin expanded 316 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+17.8% +0.0%
126 126 107 Operating profit
+41.2% +4.3%
24.0 23.0 17.0 OPM %
+316 bps +79 bps
19.0% 18.3% 15.9% Other income
+0.0% +0.0%
2.0 2.0 2.0 Net profit
+62.5% -13.3%
13.0 15.0 8.0 PAT margin %
+284 bps -159 bps
10.3% 11.9% 7.5% EPS (₹)
+64.9% -12.9%
1.55 1.78 0.94
Quality of profit
Pre-tax profit ₹17.0 Cr: core business ₹15.0 Cr, other income ₹2.0 Cr.
Core profit YoY: +66.7%
· reported profit +62.5%
Cash & debt
FY26 cash from operations ₹81.0 Cr:
188% of FY26 net profit of ₹43.0 Cr.
Borrowings ₹91.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹121 ₹126
+3.9% in line Net profit ₹5.7 ₹13.0
+126.5% above
Standouts so far
Among companies with a market cap of ₹1,000 Cr or more, so a tiny base does not top the list. Price reaction: last close against the close before the filing.
Reporting in the next three days
HCL Technologies (Mon 12 Oct), ICICI Prudential (Mon 12 Oct), RBL Bank (Mon 12 Oct), Swan Defence (Mon 12 Oct), Gujarat State (Mon 12 Oct), Swaraj Engines (Mon 12 Oct), Plastiblends India (Mon 12 Oct), UMIYA BUILDCON (Mon 12 Oct), Alkali Metals (Mon 12 Oct), Gradiente Infotainment (Mon 12 Oct), Agri-Tech (India) (Mon 12 Oct), Abhishek Integrations (Mon 12 Oct), Rudra Ecovation (Mon 12 Oct), Newtrac Foods (Mon 12 Oct), Inani Securities (Mon 12 Oct), Neil Industries (Mon 12 Oct), Adroit Industries (Mon 12 Oct), TYPHOON (Mon 12 Oct), UNIVARTS (Mon 12 Oct), VERONICAPRO (Mon 12 Oct), ICICI Prudential (Tue 13 Oct), Tata Elxsi (Tue 13 Oct), Transformers And Rectifiers (Tue 13 Oct), Anand Rathi (Tue 13 Oct) and 87 more.
Full results calendar →
How to read this page
The numbers. Each card is one company's Q1 FY27 results as filed with NSE or BSE, read from the
filing within hours of its release, in ₹ crore. We show the consolidated statement, or the standalone one when
the consolidated figures are a copy of it or have no year-ago quarter to compare with. YoY compares with the same
quarter a year earlier and QoQ with the quarter before (the previous half-year for companies that report every six months).
A swing between profit and loss is described in words: a percentage across it would mislead.
Margins. Operating margin (OPM) is operating profit, before depreciation, interest and other income,
as a share of sales; PAT margin is net profit as a share of sales. Their changes are in basis points
(100 bps = 1 percentage point).
Quality of profit. Core profit is operating profit minus interest and depreciation: what the business
itself earned before tax. The rest of pre-tax profit is other income (interest on cash, dividends, gains on
investments) and exceptional or one-off items. We flag a quarter when that share is 25% or more,
and when reported profit grew much faster than core profit. For banks we compare pre-provision profit with net
profit, since a fall in provisions can lift profit without the business growing.
Against its own trend. We do not have analyst consensus estimates, and we do not make them up. Instead
each company is measured against the path it was on: the same quarter last year, grown at the median of its
last four year-on-year growth rates (held between −50% and +100%; at least two growth rates needed). Sales
5% or more above that, or net profit 10% or more above, is "above trend";
as far below is "below trend". It answers "was this quarter better or worse than the company's own recent
run?", which consensus does not.
Cash and debt. Profit is an accounting figure; cash is harder to dress up. For each company we show
its operating cash flow for the last financial year as a share of that year's net profit (flagged under
50%, or when it is negative despite a profit), and its borrowings at the latest balance sheet
against the one six months earlier (flagged at a 25% move). Balance sheets come with the
September and March results, cash-flow statements with the March results.
Price since results. The latest close against the last close before the filing (a filing after 3:30 pm
counts from the next session). It is a fact about the market's reaction, not advice.
Market cap groups. Large cap is the 100 largest companies by market value and mid cap the next 150
(SEBI's ranking); below that, small cap is ₹5,000 Cr or more, micro cap ₹500 Cr or more, nano cap below.
Data source Quarterly results filed by listed companies with NSE and BSE (Regulation 33 of SEBI LODR), read from each filing; share prices from the exchanges; market cap and P/E from our daily fundamentals snapshot.
Last updated 12 Oct 2026, 12:20 IST
